| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMA.287.6.734 |
| P698 | PubMed publication ID | 11851540 |
| P50 | author | Noel S. Weiss | Q88546264 |
| Polly A Newcomb | Q89454622 | ||
| P2093 | author name string | Emily White | |
| William Barlow | |||
| Chi-Ling Chen | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| Hormone Replacement Therapy | Q108667313 | ||
| P304 | page(s) | 734-741 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Hormone replacement therapy in relation to breast cancer | |
| P478 | volume | 287 |
| Q92483062 | A Comparison of the Clinicopathological Features, Metastasis Sites and Survival Outcomes of Invasive Lobular, Invasive Ductal and Mixed Invasive Ductal and Lobular Breast Carcinoma |
| Q36468547 | Alcohol and breast cancer tumor subtypes in a Spanish Cohort |
| Q34132812 | Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study |
| Q36615906 | An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk |
| Q45066154 | Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma |
| Q35056541 | Black cohosh: an alternative therapy for menopause? |
| Q27012792 | Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status |
| Q35134608 | Breast cancer and post-menopausal hormone therapy |
| Q36023930 | Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study |
| Q35230186 | Breast cancer risk factors in relation to breast density (United States). |
| Q33567864 | Breast cancer, dermatofibromas and arsenic |
| Q44074291 | Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies |
| Q36106730 | Chemotherapy-induced ovarian failure: manifestations and management |
| Q99635221 | Classical and Non-Classical Progesterone Signaling in Breast Cancers |
| Q36615540 | Clinical characteristics of different histologic types of breast cancer |
| Q50334835 | Correlations between Risk Factors for Breast Cancer and Genetic Instability in Cancer Patients—A Clinical Perspective Study. |
| Q36675379 | Current breast cancer risks of hormone replacement therapy in postmenopausal women |
| Q33856406 | Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer |
| Q47441762 | Duration of hormone replacement therapy, breast tumour size and grade in a screening programme |
| Q44633005 | Effect of epimedium-derived phytoestrogen on bone turnover and bone microarchitecture in OVX-induced osteoporotic rats |
| Q33721841 | Equine estrogen-induced mammary tumors in rats |
| Q36611606 | Established breast cancer risk factors by clinically important tumour characteristics |
| Q43276874 | Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? |
| Q36953173 | Expression of the Mir-133 and Bcl-2 could be affected by swimming training in the heart of ovariectomized rats |
| Q43689285 | Factors modifying the association between hormone-replacement therapy and breast cancer risk |
| Q83102873 | Factors that influence changes in mammographic density with postmenopausal hormone therapy |
| Q33564013 | Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting |
| Q30491822 | Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk |
| Q47102209 | Genistein preserves the lungs of ovariectomized diabetic rats: addition to apoptotic and inflammatory markers in the lung. |
| Q35539421 | HRT: Decide Based on the Evidence |
| Q35563929 | HT and breast cancer risk |
| Q47689415 | Hormonal factors and breast tumor proliferation: do factors that affect cancer risk also affect tumor growth? |
| Q35048651 | Hormonal therapy and risk of breast cancer in mexican women |
| Q34572280 | Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis |
| Q74662523 | Hormone replacement therapy and breast cancer, revisited |
| Q33810016 | Hormone replacement therapy and the breast. Studies must determine the evidence |
| Q47436578 | Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study |
| Q35580329 | Hormone therapy and young-onset breast cancer. |
| Q35216824 | Hot flashes in breast cancer survivors |
| Q36972521 | Identification of risk factors for breast cancer for women in istanbul |
| Q44823539 | Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. |
| Q34179808 | Late age at first full term birth is strongly associated with lobular breast cancer |
| Q83306280 | Ligand binding by estrogen receptor beta attached to nanospheres measured by fluorescence correlation spectroscopy |
| Q35170028 | Lobular breast cancer: incidence and genetic and non-genetic risk factors |
| Q37370478 | Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort |
| Q34480625 | Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study |
| Q35608346 | Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis |
| Q36695646 | Primary systemic chemotherapy of invasive lobular carcinoma of the breast |
| Q24800282 | Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies |
| Q34420425 | Progestins and progesterone in hormone replacement therapy and the risk of breast cancer |
| Q34317537 | Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects |
| Q37453973 | Progress in osteoporosis and fracture prevention: focus on postmenopausal women |
| Q33959481 | Quantitative detection of 4-hydroxyequilenin-DNA adducts in mammalian cells using an immunoassay with a novel monoclonal antibody. |
| Q43753113 | Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma |
| Q33237199 | Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy |
| Q79103489 | Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65–79 years of age |
| Q36863482 | Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer |
| Q35906333 | Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation |
| Q34613642 | Risk factors for ductal and lobular breast cancer: results from the nurses' health study |
| Q33903091 | Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population |
| Q35108992 | Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis |
| Q35030277 | Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma |
| Q37465836 | Social and Cultural Factors Affecting Complementary and Alternative Medicine (CAM) Use during Menopause in Sydney and Bologna. |
| Q33902268 | Tamoxifen for breast cancer prevention: safety warning |
| Q79754070 | The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results |
| Q90157652 | The efficacy and safety of acupuncture for perimenopause symptom compared with different sham acupuncture control groups: A protocol of systematic review and meta-analysis |
| Q24673333 | The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes |
| Q35089975 | The menopause, hormone replacement therapy and breast cancer |
| Q42730607 | The relationship between hormone therapy use at the time of diagnosis of breast cancer and tumor characteristics |
| Q91774033 | To evaluate the efficacy and safety of PLC in perimenopausal or postmenopausal women with Hot Flashes: study protocol for a randomized controlled trial |
| Q36593545 | Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer |
| Q33823771 | Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age |
| Q35198262 | When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly |
| Q64094931 | Women on Hormone Therapy with Ischemic Stroke, Effects on Deficits and Recovery |
| Q81672835 | [Palpable lesion retromamillary and bloody secretion from the right breast] |
Search more.